RRMS
MCID: RLP002
MIFTS: 56

Relapsing-Remitting Multiple Sclerosis (RRMS)

Categories: Immune diseases, Neuronal diseases

Aliases & Classifications for Relapsing-Remitting Multiple Sclerosis

MalaCards integrated aliases for Relapsing-Remitting Multiple Sclerosis:

Name: Relapsing-Remitting Multiple Sclerosis 12 15 17
Multiple Sclerosis, Relapsing-Remitting 43 71
Relapsing Remitting Multiple Sclerosis 29 6
Relapsing-Remitting Ms 12 15
Multiple Sclerosis Relapsing-Remitting 54
Rrms 12

Classifications:



External Ids:

Disease Ontology 12 DOID:2378
MeSH 43 D020529
SNOMED-CT 67 426373005
UMLS 71 C0751967

Summaries for Relapsing-Remitting Multiple Sclerosis

Disease Ontology : 12 A multiple sclerosis that is characterized by relapse (attacks of symptom flare-ups) followed by remission (periods of recovery). Symptoms may vary from mild to severe, and relapses and remissions may last for days or months. More than 80 percent of people who have MS begin with relapsing-remitting cycles.

MalaCards based summary : Relapsing-Remitting Multiple Sclerosis, also known as multiple sclerosis, relapsing-remitting, is related to progressive multifocal leukoencephalopathy and allergic encephalomyelitis. An important gene associated with Relapsing-Remitting Multiple Sclerosis is NEAT1 (Nuclear Paraspeckle Assembly Transcript 1), and among its related pathways/superpathways are Innate Immune System and PEDF Induced Signaling. The drugs Mitoxantrone and Aspirin have been mentioned in the context of this disorder. Affiliated tissues include brain, t cells and b cells, and related phenotypes are hematopoietic system and growth/size/body region

Related Diseases for Relapsing-Remitting Multiple Sclerosis

Diseases related to Relapsing-Remitting Multiple Sclerosis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 583)
# Related Disease Score Top Affiliating Genes
1 progressive multifocal leukoencephalopathy 32.2 TNF MBP IFNB1
2 allergic encephalomyelitis 32.1 MOG MBP CCL5
3 lymphopenia 32.1 IL18 IL10 IFNG FOXP3
4 alpha/beta t-cell lymphopenia with gamma/delta t-cell expansion, severe cytomegalovirus infection, and autoimmunity 32.0 IL17A IL10 IFNG FOXP3
5 optic neuritis 31.9 TNF MOG MBP IL10 BDNF
6 secondary progressive multiple sclerosis 31.8 MMP9 MBP IL17A IL10 IFNG IFNB1
7 nasopharyngitis 31.7 TNF IL17A IFNB1
8 chickenpox 31.6 TNF IL10 IFNG IFNB1 IFNA1
9 thrombocytopenia due to platelet alloimmunization 31.6 IL17A IL10 FOXP3
10 macular retinal edema 31.6 TNF IFNB1 ICAM1
11 neuromyelitis optica 31.6 MOG MBP IL17A IFNA1
12 purpura 31.6 TNF IL10 IFNG
13 neuritis 31.5 TNF MOG MMP9 MBP IL10 IFNG
14 herpes zoster 31.5 TNF IL10 IFNG IFNA1
15 exanthem 31.4 TNF IL1RN IL10 IFNG IFNA1
16 neutropenia 31.4 TNF IL1RN IL10 IFNG IFNA1
17 acute disseminated encephalomyelitis 31.4 MOG MBP IL10 IFNB1
18 acute cystitis 31.3 TNF IL18 IL10
19 multiple sclerosis 31.3 TNF TIMP1 MX1 MOG MMP9 MBP
20 tetanus 31.3 TNF MBP IL10 IFNG
21 guillain-barre syndrome 31.3 TNF MOG MBP
22 demyelinating disease 31.2 TNF MOG MMP9 MBP IL17A IL10
23 meningoencephalitis 31.2 TNF MBP IL10 CCL5 BDNF
24 sleep disorder 31.2 TNF MOG BDNF
25 chlamydia 31.2 TNF IL18 IL17A IL10 IFNG
26 listeriosis 31.1 TNF IL10 IFNB1
27 vaginitis 31.1 TNF IL10 CCL5
28 cryptococcosis 31.1 TNF IL17A IL10 IFNG
29 autoimmune disease 31.1 TNF MOG MMP9 MBP IL1RN IL18
30 thyroiditis 31.1 TNF IL10 IFNA1 FOXP3
31 pyelonephritis 31.1 TNF IL10 IFNG CCL5
32 endocarditis 31.0 TNF IL17A IL10 IFNG
33 primary progressive multiple sclerosis 31.0 TNF TIMP1 MX1 MOG MMP9 MBP
34 hepatitis a 31.0 TNF IL10 IFNG IFNA1
35 idiopathic neutropenia 31.0 TNF IL1RN IL10 CCL5
36 autoimmune hepatitis 31.0 TNF IL10 IFNA1 FOXP3
37 pericarditis 31.0 TNF IL1RN IFNG
38 dermatitis 31.0 TNF IL18 IL17A IL10 IFNG
39 spondylitis 30.9 TNF IL1RN IL17A IL10 IFNG
40 chronic inflammatory demyelinating polyradiculoneuropathy 30.9 MBP IL17A IL10 IFNG IFNB1 CCL5
41 lymphadenitis 30.9 TNF IL18 IL10 IFNG ICAM1
42 acute pancreatitis 30.9 TNF IL1RN IL18 IL10
43 diarrhea 30.8 TNF IL10 IFNG IFNB1 IFNA1 FOXP3
44 glioblastoma multiforme 30.8 MMP9 IFNG IFNB1 IFNA1 ICAM1 FOXP3
45 spondyloarthropathy 1 30.7 TNF IL1RN IL17A
46 peripheral nervous system disease 30.7 TNF MOG MBP IL17A IL10 IFNG
47 amyotrophic lateral sclerosis 1 30.7 TNF TIMP1 NEAT1 IL17A IFNB1 HNRNPA1
48 celiac disease 1 30.7 TNF IL18 IL17A IL10 IFNG IFNA1
49 encephalitis 30.7 TNF MX1 MOG IL10 IFNB1 IFNA1
50 respiratory failure 30.6 TNF TIMP1 IL1RN IL10 CCL5

Graphical network of the top 20 diseases related to Relapsing-Remitting Multiple Sclerosis:



Diseases related to Relapsing-Remitting Multiple Sclerosis

Symptoms & Phenotypes for Relapsing-Remitting Multiple Sclerosis

MGI Mouse Phenotypes related to Relapsing-Remitting Multiple Sclerosis:

45 (show all 11)
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.28 CCL5 FOXP3 ICAM1 IFNB1 IFNG IL10
2 growth/size/body region MP:0005378 10.27 BDNF FOXP3 ICAM1 IFNG IL10 IL17A
3 cellular MP:0005384 10.24 BDNF FOXP3 ICAM1 IFNG IL10 IL18
4 homeostasis/metabolism MP:0005376 10.22 BDNF FOXP3 ICAM1 IFNB1 IFNG IL10
5 immune system MP:0005387 10.21 CCL5 FOXP3 ICAM1 IFNB1 IFNG IL10
6 digestive/alimentary MP:0005381 10.13 BDNF FOXP3 ICAM1 IFNG IL10 IL17A
7 integument MP:0010771 10.02 BDNF FOXP3 ICAM1 IFNG IL10 IL17A
8 neoplasm MP:0002006 9.8 ICAM1 IFNB1 IFNG IL10 MMP9 TIMP1
9 no phenotypic analysis MP:0003012 9.7 BDNF FOXP3 IFNB1 IFNG IL10 IL17A
10 respiratory system MP:0005388 9.56 BDNF FOXP3 IFNG IL10 IL17A MMP9
11 vision/eye MP:0005391 9.32 BDNF FOXP3 ICAM1 IFNG IL10 IL18

Drugs & Therapeutics for Relapsing-Remitting Multiple Sclerosis

Drugs for Relapsing-Remitting Multiple Sclerosis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 304)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Mitoxantrone Approved, Investigational Phase 4 65271-80-9 4212
2
Aspirin Approved, Vet_approved Phase 4 50-78-2 2244
3
Esomeprazole Approved, Investigational Phase 4 161796-78-7, 119141-88-7, 161973-10-0 9568614 4594
4
Ibuprofen Approved Phase 4 15687-27-1 3672
5
Tocopherol Approved, Investigational Phase 4 1406-66-2, 54-28-4 14986
6
Titanium dioxide Approved Phase 4 13463-67-7
7
Phylloquinone Approved, Investigational Phase 4 84-80-0
8
leucovorin Approved Phase 4 58-05-9 6006 143
9
Methotrexate Approved Phase 4 59-05-2, 1959-05-2 126941
10
Donepezil Approved Phase 4 120014-06-4 3152
11
Doxycycline Approved, Investigational, Vet_approved Phase 4 564-25-0 54671203
12
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 6741
13
Prednisolone phosphate Approved, Vet_approved Phase 4 302-25-0
14
Methylprednisolone hemisuccinate Approved Phase 4 2921-57-5
15 Prednisolone acetate Approved, Vet_approved Phase 4 52-21-1
16
Prednisolone Approved, Vet_approved Phase 4 50-24-8 5755
17
Cladribine Approved, Investigational Phase 4 4291-63-8 20279
18
Ocrelizumab Approved, Investigational Phase 4 637334-45-3
19
Citalopram Approved Phase 4 59729-33-8 2771
20
Norepinephrine Approved Phase 4 51-41-2 439260
21
Fluoxetine Approved, Vet_approved Phase 4 54910-89-3 3386
22
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
23
Simethicone Approved Phase 4 8050-81-5
24
Loperamide Approved Phase 4 53179-11-6 3955
25
Tretinoin Approved, Investigational, Nutraceutical Phase 4 302-79-4 444795 5538
26
Vitamin E Approved, Nutraceutical, Vet_approved Phase 4 59-02-9 14985
27
Menadione Approved, Nutraceutical Phase 4 58-27-5 4055
28
Folic acid Approved, Nutraceutical, Vet_approved Phase 4 59-30-3 6037
29
Vitamin A Approved, Nutraceutical, Vet_approved Phase 4 22737-96-8, 68-26-8, 11103-57-4 9904001 445354
30
Vitamin D Approved, Nutraceutical, Vet_approved Phase 4 1406-16-2
31
Vitamin D3 Approved, Nutraceutical Phase 4 67-97-0 5280795 6221
32
Ergocalciferol Approved, Nutraceutical Phase 4 50-14-6 5280793
33 Tocotrienol Investigational Phase 4 6829-55-6
34 Menaquinone Investigational Phase 4 1182-68-9
35
Prednisolone hemisuccinate Experimental Phase 4 2920-86-7
36 Analgesics Phase 4
37 Anti-Inflammatory Agents, Non-Steroidal Phase 4
38 Antioxidants Phase 4
39 Cyclooxygenase Inhibitors Phase 4
40 Platelet Aggregation Inhibitors Phase 4
41 Iron-Dextran Complex Phase 4
42 Histamine H1 Antagonists, Non-Sedating Phase 4
43 Proton Pump Inhibitors Phase 4
44 Omega 3 Fatty Acid Phase 4
45 Sunflower Phase 4
46 Tocotrienols Phase 4
47 Tocopherols Phase 4
48 Hemostatics Phase 4
49 Antifibrinolytic Agents Phase 4
50 Vitamin K Phase 4

Interventional clinical trials:

(show top 50) (show all 644)
# Name Status NCT ID Phase Drugs
1 A 32-week, Monocentric, Exploratory, Single Arm Study to Assess Immune Function and MRI Disease Activity in Patients With RRMS Transferred From Previous Treatment With Natalizumab to Gilenya® (Fingolimod) Unknown status NCT02325440 Phase 4 Fingolimod;Natalizumab
2 A Multicenter Longitudinal Cross-sectional Pilot Study, to Compare RNFL Thickness Measured by OCT After Treatment With Glatiramer or After no Treatment in Patients With CIS With or Without Optic Neuritis or With Early RRMS Unknown status NCT00910598 Phase 4 glatiramer acetate
3 Impact of Vitamin A Supplementation on RAR Gene Expression in PBMC Cells in Multiple Sclerotic Patients Unknown status NCT01705457 Phase 4 Dietary Supplement: vitamin A;placebo
4 Impact of Vitamin A Supplementation on Disease Activity and Progression in Multiple Sclerotic (MS) Patients Unknown status NCT01417273 Phase 4 Drug: placebo
5 The Impact of Vitamin A Supplementation on Gene Expression of Cytokine Secreted by CD4+ T Lymphocyte in Multiple Sclerosis Patients Unknown status NCT01407211 Phase 4
6 Colecalciferol as an Add-on Treatment to Subcutaneously Administered Interferon-beta-1b for Treatment of MS Unknown status NCT01339676 Phase 4 Colecalciferol;Placebo capsules
7 Alemtuzumab in Autoimmune Inflammatory Neurodegeneration: Mechanisms of Action and Neuroprotective Potential Unknown status NCT02419378 Phase 4 Alemtuzumab
8 Investigating Indirect Mechanism of Neuroprotection of Tecfidera® (Dimethyl Fumarate) in RRMS and Progressive Patients Unknown status NCT03092544 Phase 4 dimethyl fumarate
9 A 6-month Multicenter, Single-arm, Open-label Study to Investigate Changes in Biomarkers After Initiation of Treatment With 0.5 mg Fingolimod (FTY720) in Patients With Relapsing-remitting Multiple Sclerosis Completed NCT01310166 Phase 4 Fingolimod
10 Effects of Fingolimod (Gilenya®) on Cytokine and Chemokine Levels in Relapsing Remitting Multiple Sclerosis Patients Completed NCT02373098 Phase 4 Fingolimod 0.5 mg
11 Evaluation of Emotional Disorders During Treatment by Interferon Beta in Relapsing-remitting Multiple Sclerosis Patients Completed NCT01201343 Phase 4 Interferon beta-1a
12 Long-term Follow up of Patients With Relapsing-remitting Multiple Sclerosis Enrolled in the Multicenter, Single-arm, Open-label Biobank Study (CFTY720DDE01), to Investigate Changes in Biomarkers After 48 Months of Treatment With 0.5 mg Fingolimod (FTY720) Completed NCT02720107 Phase 4 fingolimod
13 A 6-month, Randomized, Active Comparator, Open-label, Multi-Center Study to Evaluate Patient Outcomes, Safety and Tolerability of (Fingolimod) 0.5 mg/Day in Patients With Relapsing Remitting Multiple Sclerosis Who Are Candidates for Multiple Sclerosis (MS) Therapy Change From Previous Disease Modifying Therapy (DMT) Completed NCT01534182 Phase 4 Fingolimod;Interferon beta - 1a (IFN);Glatiramer acetate (GA)
14 Open Label Study to Evaluate the Safety of Copaxone® and to Monitor the Neurologic Course of Disease in Multiple Sclerosis Patients Treated With Copaxone Completed NCT00203021 Phase 4 Glatiramer acetate
15 A Multicenter, Open-Label Study Evaluating the Effectiveness of Oral Tecfidera™ (Dimethyl Fumarate) on MS Disease Activity and Patient-Reported Outcomes in Subjects With Relapsing-Remitting Multiple Sclerosis in the Real-World Setting Completed NCT01930708 Phase 4 dimethyl fumarate
16 A Multi-centre, Open-label, Non-randomised, Parallel Group Clinical Trial to Assess the Efficacy of Fingolimod in Naive Patients Versus Fingolimod in Patients Previously Treated With Interferons or Glatiramer Acetate, Based on the Presence of Relapses in Patients With Relapsing-remitting Multiple Sclerosis. Completed NCT01498887 Phase 4 Fingolimod (FTY720)
17 A 4-month, Prospective, Open-label, Multi-center Phase IV Study to Assess Response to Fingolimod Initiation According to Coping Profile in Adult Patients With Highly Active Relapsing Remitting Multiple Sclerosis in France Completed NCT01420055 Phase 4 fingolimod
18 A Phase IV Multicenter Randomized Study to Assess the Impact of a Patient Support Program (MinSupport Plus) on Health Related Quality of Life (HRQoL) and Adherence in Patients With Relapsing Remitting Multiple Sclerosis Administered Rebif® With the RebiSmart Device Completed NCT01791244 Phase 4 Rebif®
19 A Phase IV, Randomized, Prospective, US-based, Multicenter, Cross-over Study Evaluating Subject Ease-of-use With Rebif® Rebidose® and Rebiject II® Autoinjectors in Subjects With Relapsing Remitting Multiple Sclerosis (RRMS) Treated With REBIF® 44 mcg Subcutaneously Three Times a Week Completed NCT02019550 Phase 4
20 A Randomized, Rater-blinded, Multicenter, Parallel-group Study Comparing the Efficacy and Safety of Betaseron 250 µg Subcutaneously Every Other Day With Avonex 30 µg Intramuscularly Once Per Week in Relapsing-remitting Multiple Sclerosis Patients Previously Treated With Avonex Completed NCT00206648 Phase 4 Betaferon/Betaseron;Betaferon/Betaseron
21 A Prospective, Open-label, Non-randomized, Clinical Trial to Evaluate the Safety and Efficacy in RUSsian RRMS Patients on One Year Treatment With Natalizumab (TYSabri®). Completed NCT02142205 Phase 4
22 CONFIDENCE: A Multinational, Multicenter, Randomized, Parallel Group, Open-Label Study to Assess Medication Satisfaction in Patients With Relapsing Remitting Multiple Sclerosis (RRMS) Treated With Subcutaneous Injections of Copaxone(R) (Glatiramer Acetate) 40 mg/mL Three Times a Week Compared to 20 mg/mL Daily Completed NCT02499900 Phase 4 Copaxone®
23 Multicentre, Single Arm, Open, Phase IV Study To Evaluate Immunogenicity And Safety Of Subcutaneous r-hIFN Beta-1a (Rebif®) Using Clone 484-39 In The Treatment Of Relapsing Remitting Multiple Sclerosis Completed NCT00367484 Phase 4
24 Alemtuzumab on Surrogate Markers of Disease Activity and Repair Using Advanced MRI Measures in Subjects With Relapsing Remitting Multiple Sclerosis Completed NCT01395316 Phase 4 Alemtuzumab
25 A Prospective, Open-label, Non-randomized, Clinical Trial to Determine if Natalizumab (Tysabri®) Improves Ambulatory Measures in Relapsing-remitting Multiple Sclerosis (RRMS) Patients "TIMER" Study Completed NCT00871780 Phase 4 BG00002 (natalizumab)
26 Multicenter Interventional Phase IV Study for the Assessment of the Effects on Patient's Satisfaction of Plegridy (Pre-filled Pen) in Subjects With Relapsing-remitting Multiple Sclerosis Unsatisfied With Other Injectable Subcutaneous Interferons (PLATINUM) Completed NCT02587065 Phase 4 peginterferon beta-1a
27 A Phase 4, Randomized, Double-Blind Study With a Safety Extension Period to Evaluate the Effect of Aspirin on Flushing Events in Subjects With Relapsing-Remitting Multiple Sclerosis Treated With Tecfidera® (Dimethyl Fumarate) Delayed-Release Capsules Completed NCT02090413 Phase 4 dimethyl fumarate;acetylsalicylic acid;ASA-Placebo
28 A Multicenter, Open-Label, Single-Arm Study to Evaluate Gastrointestinal Tolerability in Subjects With Relapsing-Remitting Multiple Sclerosis Receiving Dimethyl Fumarate (TOLERATE) Completed NCT02125604 Phase 4 dimethyl fumarate
29 A 3-year Multi-center Study to Describe the Long Term Changes of Optical Coherence Tomography (OCT) Parameters in Patients Under Treatment With Gilenya® Completed NCT01705236 Phase 4 Fingolimod
30 Single Arm Study To Assess Comprehensive Infusion Guidance For The Management Of The Infusion- Associated Reactions (IARs) In Relapsing-Remitting Multiple Sclerosis (RRMS) Patients Treated With LEMTRADA Completed NCT02205489 Phase 4 Alemtuzumab GZ402673;cetirizine;ranitidine;methylprednisolone;methylprednisolone;aciclovir;esomeprazole;ibuprofen;paracetamol
31 A 18-month, Open-label, Rater-blinded, Randomized, Multi-center, Active-controlled, Parallel-group Pilot Study to Assess Efficacy and Safety of Fingolimod in Comparison to Interferon Beta 1b in Treating the Cognitive Symptoms Associated to Relapsing-remitting Multiple Sclerosis and to Assess Possible Relationship of These Effects to Regional Brain Atrophy Completed NCT01333501 Phase 4 Fingolimod;Interferon beta 1b
32 The AVANTAGE Study - A Randomized, Multicenter, Phase IV, Open-label Prospective Study Comparing Injection Site Reaction and Injection Site Pain in Patients With Relapsing Remitting Multiple Sclerosis (RRMS) or After a First Demyelinating Event Suggestive of MS Newly Started on Interferon Beta-1b (Betaferon®) or Interferon Beta-1a (Rebif®). Completed NCT00317941 Phase 4 Betaferon/Betaseron;Rebif;Betaferon/Betaseron
33 Evaluation of the Correlation Between the MS Functional Composite Index and Two Quality of Life Scales (MS54 and AMS Quality of Life) in Relapsing MS Patients Treated With Interferon Beta-1a (AVONEX®) Completed NCT00534261 Phase 4 Interferon beta-1a
34 A 6-month, Randomized, Active Comparator, Open-label, Multi-Center Study to Evaluate Patient Outcomes, Safety and Tolerability of Fingolimod (FTY720) 0.5 mg/Day in Patients With Relapsing Remitting Multiple Sclerosis Who Are Candidates for MS Therapy Change From Previous Disease Modifying Therapy (EPOC) Completed NCT01317004 Phase 4 Fingolimod;Standard MS DMT
35 Phase IV, Multicenter, Open Label, Randomized Study of Rebif® 44 mcg Administered Three Times Per Week by Subcutaneous Injection Compared With Copaxone® 20 mg Administered Daily by Subcutaneous Injection in the Treatment of Relapsing Remitting Multiple Sclerosis Completed NCT00078338 Phase 4 Rebif®;Copaxone®
36 Efficacy of Fish Oil on Serum TNFα, IL-1β, IL-6, Oxidative Stress Markers in Multiple Sclerosis Treated With Interferon Beta 1-b Completed NCT01842191 Phase 4
37 A 12-month, Prospective, Randomized, Active-controlled, Open-label Study to Evaluate the Patient Retention of Fingolimod vs. Approved First-line Disease Modifying Therapies in Adults With Relapsing Remitting Multiple Sclerosis (PREFERMS) Completed NCT01623596 Phase 4 Fingolimod;Disease Modifying therapy
38 A 24-week, Multicenter, Exploratory, Two Arm Study to Assess the Effect of Dimethyl Fumarate on Immune-Modulatory Action on T Cells in Patients With Relapsing Remitting Multiple Sclerosis (DIMAT-MS) Completed NCT02461069 Phase 4 Dimethyl fumarate
39 A Multi-Centre, Open Label Study to Investigate the Recovery of IFN-beta Efficacy in Relapsing-Remitting Multiple Sclerosis Patients With Neutralising IFN-beta Antibodies and Reduced Bioavailability Completed NCT00493116 Phase 4 Interferon-beta-1a;methylprednisolone
40 A Multicentre, Randomized, Double-blind, Placebo-controlled, Parallel Group Trial Investigating Methylprednisolone in Combination With Interferon-beta-1a for the Treatment of Patients With Relapsing-remitting Multiple Sclerosis Completed NCT00168766 Phase 4 Interferon-beta-1a (Avonex) plus methylprednisolone
41 A Multicentre, Open Label, Non-Comparative Trial Investigating the Recovering of INF-Beta Efficacy in Breakthrough Relapsing-Remitting Multiple Sclerosis Patients With Neutralizing Interferon-Beta Antibodies Completed NCT00492466 Phase 4 Interferon-beta-1a;methylprednisolone
42 A Multi-Center, Randomized, Blinded, Parallel-Group Study of AVONEX Compared With AVONEX in Combination With Oral Methotrexate, Intravenous Methylprednisolone, or Both in Subjects With Relapsing Remitting MS Who Have Breakthrough Disease on AVONEX Monotherapy. Completed NCT00112034 Phase 4 Methotrexate;IV methylprednisolone
43 De-escalation After Natalizumab Treatment With Interferon-beta-1b in Patients With Relapsing-remitting Multiple Sclerosis Completed NCT01144052 Phase 4 interferon beta-1b;Natalizumab
44 A Double-Blind, Crossover Trial of Aricept® in Memory-Impaired Patients With Multiple Sclerosis: A Phase IV Demonstration of Functional MRI (fMRI) as a Surrogate Marker of Brain Activity Associated With Improvement in Memory Function Completed NCT00315367 Phase 4 Donepezil HCI (drug)
45 Effects of VITAmin K in Lessening Erythema Grade Associated to Injection Site Reactions in Patients Treated With PlegridY (VITALITY) Completed NCT03091569 Phase 4
46 Phase IV, Multicenter, Open Label, Randomized Study of Rebif® 44mcg Administered Three Times Per Week by Subcutaneous Injection Compared With no Treatment in the Therapy of Relapsing Multiple Sclerosis After Mitoxantrone Completed NCT01142466 Phase 4 Interferon beta-1a (Rebif)
47 The Study of the Effects of Vitamin A Supplementation on Immune System and Th1/Th2 Balance in Patients With Multiple Sclerosis Completed NCT01225289 Phase 4 Placebo
48 A Multi-centre, Double Blind, Randomised, Placebo Controlled, Parallel Group Study Investigating Simvastatin as an Add-on Treatment IM Administered Interferon-beta-1a for the Treatment of Relapsing-Remitting Multiple Sclerosis Completed NCT00492765 Phase 4 Interferon-beta-1a;Simvastatin;Placebo
49 A Twenty-four Week, Two Arm, Pilot Trial to Evaluate Remyelination/ Demyelination, Gray Matter Volume and Iron Deposition in the Central Nervous System (CNS) and Immune Status of Subjects With Relapsing-remitting Multiple Sclerosis (RRMS) Treated With Rebif® 44 mcg Subcutaneously (sc) Three Times a Week (Tiw) Compared to a Healthy Control Group Completed NCT01085318 Phase 4 Rebif
50 Fatigue Outcomes of Copaxone Users in Relapsing-remitting Multiple Sclerosis Completed NCT00267319 Phase 4 Glatiramer acetate

Search NIH Clinical Center for Relapsing-Remitting Multiple Sclerosis

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Glatiramer
glatiramer acetate

Cochrane evidence based reviews: multiple sclerosis, relapsing-remitting

Genetic Tests for Relapsing-Remitting Multiple Sclerosis

Genetic tests related to Relapsing-Remitting Multiple Sclerosis:

# Genetic test Affiliating Genes
1 Relapsing Remitting Multiple Sclerosis 29

Anatomical Context for Relapsing-Remitting Multiple Sclerosis

MalaCards organs/tissues related to Relapsing-Remitting Multiple Sclerosis:

40
Brain, T Cells, B Cells, Testes, Spinal Cord, Bone, Monocytes

Publications for Relapsing-Remitting Multiple Sclerosis

Articles related to Relapsing-Remitting Multiple Sclerosis:

(show top 50) (show all 6666)
# Title Authors PMID Year
1
Demyelination as a complication of new immunomodulatory treatments. 54 61
20442571 2010
2
Interferon-beta inhibits Th17 cell differentiation in patients with multiple sclerosis. 61 54
20384573 2010
3
[Long term effect of interferon-beta on disease severity in relapsing-remitting multiple sclerosis patients]. 61 54
20443171 2010
4
Novel approaches to detect serum biomarkers for clinical response to interferon-beta treatment in multiple sclerosis. 54 61
20463963 2010
5
T helper type 1 and 17 cells determine efficacy of interferon-beta in multiple sclerosis and experimental encephalomyelitis. 61 54
20348925 2010
6
Increased osteopontin plasma levels in multiple sclerosis patients correlate with bone-specific markers. 54 61
20086024 2010
7
No significant effect of orally administered chemokine receptor 1 antagonist on intercellular adhesion molecule-3 expression in relapsing--remitting multiple sclerosis patients. 61 54
20086017 2010
8
Effect of IFN-beta therapy on the frequency and function of CD4(+)CD25(+) regulatory T cells and Foxp3 gene expression in relapsing-remitting multiple sclerosis (RRMS): a preliminary study. 61 54
19932513 2010
9
Measures in the first year of therapy predict the response to interferon beta in MS. 61 54
19542263 2009
10
Recombinant interferon-beta therapy and neuromuscular disorders. 61 54
19443048 2009
11
Antibodies against interferon-beta in multiple sclerosis. 61 54
19467718 2009
12
Interferon-beta modifies the peripheral blood cell cytokine secretion in patients with multiple sclerosis. 61 54
19289181 2009
13
Effect of statins on clinical and molecular responses to intramuscular interferon beta-1a. 54 61
19506220 2009
14
Interferon-beta therapy up-regulates BDNF secretion from PBMCs of MS patients through a CD40-dependent mechanism. 54 61
19419774 2009
15
The clinical effect of neutralizing antibodies against interferon-beta is independent of the type of interferon-beta used for patients with relapsing-remitting multiple sclerosis. 54 61
19299439 2009
16
Natalizumab is effective as second line therapy in the treatment of relapsing remitting multiple sclerosis. 54 61
19187261 2009
17
Omega-3 fatty acid supplementation decreases matrix metalloproteinase-9 production in relapsing-remitting multiple sclerosis. 54 61
19171471 2009
18
A longitudinal observation of brain-derived neurotrophic factor mRNA levels in patients with relapsing-remitting multiple sclerosis. 61 54
19071096 2009
19
Natalizumab use in pediatric multiple sclerosis. 54 61
19064754 2008
20
[Approach to find new therapies for MS from clinical view]. 54 61
19198123 2008
21
Effects of natalizumab treatment on Foxp3+ T regulatory cells. 54 61
18836525 2008
22
Clinical markers of therapeutic response to disease modifying drugs. 54 61
18690494 2008
23
Interferon-beta induces brain-derived neurotrophic factor in peripheral blood mononuclear cells of multiple sclerosis patients. 61 54
18555540 2008
24
Relationship between MRI lesion activity and response to IFN-beta in relapsing-remitting multiple sclerosis patients. 61 54
18562504 2008
25
Effects of interferon-beta on co-signaling molecules: upregulation of CD40, CD86 and PD-L2 on monocytes in relation to clinical response to interferon-beta treatment in patients with multiple sclerosis. 54 61
17942524 2008
26
Interleukin-10 and interleukin-12 modulation in patients with relapsing-remitting multiple sclerosis on therapy with interferon-beta 1a: differences in responders and non responders. 54 61
18686100 2008
27
The blood-central nervous system barriers actively control immune cell entry into the central nervous system. 61 54
18673197 2008
28
Clinical parameters to predict response to interferon in relapsing multiple sclerosis. 61 54
18716412 2008
29
Long-term adherence to interferon beta therapy in relapsing-remitting multiple sclerosis. 54 61
18057899 2008
30
The effect of disease activity on leptin, leptin receptor and suppressor of cytokine signalling-3 expression in relapsing-remitting multiple sclerosis. 61 54
17904647 2007
31
CCR7 expression on peripheral blood lymphocytes is up-regulated following treatment of multiple sclerosis with interferon-beta. 61 54
17711620 2007
32
Comparison of interferon beta products and azathioprine in the treatment of relapsing-remitting multiple sclerosis. 54 61
18074075 2007
33
Outcome of beta-interferon treatment in relapsing-remitting multiple sclerosis: a Bayesian analysis. 54 61
17694348 2007
34
TRAIL, CXCL10 and CCL2 plasma levels during long-term Interferon-beta treatment of patients with multiple sclerosis correlate with flu-like adverse effects but do not predict therapeutic response. 54 61
17884184 2007
35
Diminished myelin-specific T cell activation associated with increase in CTLA4 and Fas molecules in multiple sclerosis patients treated with IFN-beta. 54 61
17970696 2007
36
The IgG subclass-specificities of anti-IFNbeta antibodies change with time and differ between the IFNbeta products in relapsing remitting multiple sclerosis patients. 61 54
17825927 2007
37
Expression of ionotropic glutamate receptor GLUR3 and effects of glutamate on MBP- and MOG-specific lymphocyte activation and chemotactic migration in multiple sclerosis patients. 54 61
17628700 2007
38
Erythema nodosum and glatiramer acetate treatment in relapsing-remitting multiple sclerosis. 61 54
17881403 2007
39
Expansion of CD56Bright natural killer cells in the peripheral blood of multiple sclerosis patients treated with interferon-beta. 61 54
17603762 2007
40
Interferons in multiple sclerosis: ten years' experience. 61 54
17574320 2007
41
New natural history of interferon-beta-treated relapsing multiple sclerosis. 54 61
17444502 2007
42
Predicting beta-interferon failure in relapsing-remitting multiple sclerosis. 61 54
17439902 2007
43
Cytokine changes during interferon-beta therapy in multiple sclerosis: correlations with interferon dose and MRI response. 54 61
17328965 2007
44
Expression of biomarkers of interferon type I in patients suffering from chronic diseases. 54 61
17223968 2007
45
Interferon-beta mediates opposing effects on interferon-gamma-dependent Interleukin-12 p70 secretion by human monocyte-derived dendritic cells. 61 54
17257215 2007
46
CXCL11 (Interferon-inducible T-cell alpha chemoattractant) and interleukin-18 in relapsing-remitting multiple sclerosis patients treated with methylprednisolone. 61 54
17827967 2007
47
Interferon-beta1b treatment modulates cytokines in patients with primary progressive multiple sclerosis. 54 61
17083335 2006
48
Persistence of neutralizing antibodies after discontinuation of IFNbeta therapy in patients with relapsing-remitting multiple sclerosis. 61 54
16764336 2006
49
Absence of cerebrospinal fluid oligoclonal bands is associated with delayed disability progression in relapsing-remitting MS patients treated with interferon-beta. 61 54
16473370 2006
50
Predictors of long-term clinical response to interferon beta therapy in relapsing multiple sclerosis. 54 61
16151600 2006

Variations for Relapsing-Remitting Multiple Sclerosis

ClinVar genetic disease variations for Relapsing-Remitting Multiple Sclerosis:

6 ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 HNRNPA1 NM_031157.4(HNRNPA1):c.982A>C (p.Met328Leu)SNV Likely pathogenic 135597 rs483353024 12:54677670-54677670 12:54283886-54283886
2 HNRNPA1 NM_031157.4(HNRNPA1):c.995A>G (p.Asn332Ser)SNV Likely pathogenic 135599 rs3207617 12:54677683-54677683 12:54283899-54283899
3 HNRNPA1 NM_031157.4(HNRNPA1):c.911G>A (p.Ser304Asn)SNV Uncertain significance 135590 rs483353020 12:54677599-54677599 12:54283815-54283815
4 HNRNPA1 NM_031157.4(HNRNPA1):c.931A>G (p.Ser311Gly)SNV Uncertain significance 135591 rs483353021 12:54677619-54677619 12:54283835-54283835
5 HNRNPA1 NM_031157.4(HNRNPA1):c.1093A>G (p.Ser365Gly)SNV Likely benign 135610 rs483353026 12:54678071-54678071 12:54284287-54284287
6 HNRNPA1 NM_031157.4(HNRNPA1):c.1096T>C (p.Tyr366His)SNV Likely benign 135611 rs483353027 12:54678074-54678074 12:54284290-54284290
7 HNRNPA1 NM_031157.4(HNRNPA1):c.1111A>G (p.Arg371Gly)SNV Likely benign 135614 rs3206707 12:54678089-54678089 12:54284305-54284305

Expression for Relapsing-Remitting Multiple Sclerosis

Search GEO for disease gene expression data for Relapsing-Remitting Multiple Sclerosis.

Pathways for Relapsing-Remitting Multiple Sclerosis

Pathways related to Relapsing-Remitting Multiple Sclerosis according to GeneCards Suite gene sharing:

(show all 49)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.05 TNF TIMP1 MX1 MMP9 IL1RN IL18
2
Show member pathways
13.69 TNF TIMP1 IL1RN IL18 IL17A IL10
3
Show member pathways
13.54 TNF TIMP1 IL18 IL17A IL10 IFNG
4
Show member pathways
13.3 TNF TIMP1 IL18 IL17A IL10 CCL5
5
Show member pathways
13.08 TNF MX1 MMP9 IL10 IFNG IFNB1
6
Show member pathways
13.08 TNF TIMP1 MX1 MMP9 IL1RN IL18
7
Show member pathways
12.88 TNF IL17A IL10 IFNG IFNA1 ICAM1
8
Show member pathways
12.8 TNF MX1 IL18 IFNG IFNB1 IFNA1
9 12.79 TNF IFNG IFNB1 IFNA1 CCL5
10
Show member pathways
12.72 TNF IL1RN IL18 IFNB1 IFNA1
11
Show member pathways
12.65 TNF IL18 IL17A IL10 IFNG FOXP3
12
Show member pathways
12.64 TNF TIMP1 IL18 IL17A IL10 IFNG
13
Show member pathways
12.55 MX1 IFNG IFNB1 IFNA1 ICAM1
14
Show member pathways
12.53 TNF IFNG IFNB1 IFNA1 ICAM1
15 12.48 TNF IL1RN IL17A IL10 IFNG IFNA1
16 12.39 TNF IL18 IFNB1 CCL5
17
Show member pathways
12.33 TNF MMP9 IL17A IFNG
18
Show member pathways
12.33 TNF IL18 IL10 CCL5
19
Show member pathways
12.33 TNF IFNG ICAM1 CCL5
20 12.29 TNF IL18 IFNB1 IFNA1 CCL5
21 12.24 TNF IL18 IL10 IFNG IFNB1 IFNA1
22
Show member pathways
12.22 TNF IFNG IFNB1 IFNA1
23 12.19 TNF IL1RN IL10 BDNF
24 12.11 TNF MMP9 IFNG ICAM1
25 12.03 TNF IL18 IL10 IFNB1
26 12.03 TNF MMP9 IFNB1 ICAM1 CCL5
27 12.01 TNF MMP9 MBP IFNG ICAM1 BDNF
28
Show member pathways
11.99 TNF IL18 IL17A IL10 IFNG
29 11.86 TNF TIMP1 MMP9 IL18 IL17A IL10
30
Show member pathways
11.86 TNF TIMP1 MX1 IL18 IL17A IL10
31 11.85 TNF IL18 IL17A IFNG ICAM1 CCL5
32 11.83 TNF IL18 IL17A IL10 IFNG
33 11.81 TNF IL10 IFNG IFNB1
34
Show member pathways
11.76 TNF IFNG FOXP3
35
Show member pathways
11.72 TNF MMP9 IFNG ICAM1
36 11.72 TNF TIMP1 MMP9 CCL5
37 11.57 TNF IL18 IL10 IFNG ICAM1
38 11.54 TNF IL18 IFNG
39 11.54 TNF MMP9 ICAM1
40 11.51 IL10 IFNG FOXP3
41
Show member pathways
11.43 TNF IL10 IFNG FOXP3
42 11.41 IFNG IFNB1 ICAM1
43 11.4 TNF IL18 IL10 IFNG ICAM1
44 11.35 TNF IL18 IL17A IFNG
45 11.3 TNF IL10 IFNG IFNB1
46 11.21 TNF IFNB1 CCL5
47 11.12 TIMP1 MMP9 IL18 IFNG ICAM1
48 11.05 TNF TIMP1 IL18 IL17A IL10 CCL5
49 10.86 TNF TIMP1 IL1RN IL18 IL10 ICAM1

GO Terms for Relapsing-Remitting Multiple Sclerosis

Cellular components related to Relapsing-Remitting Multiple Sclerosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.73 TNF TIMP1 MMP9 IL1RN IL18 IL17A
2 extracellular space GO:0005615 9.44 TNF TIMP1 MMP9 IL1RN IL18 IL17A

Biological processes related to Relapsing-Remitting Multiple Sclerosis according to GeneCards Suite gene sharing:

(show all 46)
# Name GO ID Score Top Affiliating Genes
1 inflammatory response GO:0006954 10.04 TNF IL1RN IL18 IL17A CCL5
2 defense response to virus GO:0051607 9.96 MX1 IFNG IFNB1 IFNA1
3 defense response GO:0006952 9.92 TNF MX1 IFNB1 IFNA1
4 cellular response to interleukin-1 GO:0071347 9.87 IL17A ICAM1 CCL5
5 B cell differentiation GO:0030183 9.86 IL10 IFNB1 IFNA1
6 regulation of insulin secretion GO:0050796 9.85 TNF IFNG CCL5
7 cellular response to organic cyclic compound GO:0071407 9.85 TNF IL18 CCL5
8 response to glucocorticoid GO:0051384 9.85 TNF IL1RN IL10
9 type I interferon signaling pathway GO:0060337 9.85 MX1 IFNB1 IFNA1
10 positive regulation of smooth muscle cell proliferation GO:0048661 9.83 TNF IL18 CCL5
11 positive regulation of vascular smooth muscle cell proliferation GO:1904707 9.81 TNF MMP9 IL10
12 positive regulation of inflammatory response GO:0050729 9.8 TNF NEAT1 IL18 IFNG
13 positive regulation of nitric oxide biosynthetic process GO:0045429 9.79 TNF IFNG ICAM1
14 B cell proliferation GO:0042100 9.78 IL10 IFNB1 IFNA1
15 negative regulation of interleukin-6 production GO:0032715 9.77 TNF IL10 FOXP3
16 lipopolysaccharide-mediated signaling pathway GO:0031663 9.77 TNF IL18 CCL5
17 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.76 TNF IL18 IFNG CCL5
18 immune response GO:0006955 9.76 TNF MBP IL1RN IL18 IL17A IL10
19 positive regulation of cytokine secretion GO:0050715 9.74 TNF IL10 IFNG
20 positive regulation of JAK-STAT cascade GO:0046427 9.73 TNF IL10 CCL5
21 humoral immune response GO:0006959 9.73 TNF IFNG IFNB1 IFNA1
22 positive regulation of chemokine (C-X-C motif) ligand 2 production GO:2000343 9.7 TNF MBP
23 positive regulation of neuroinflammatory response GO:0150078 9.7 TNF IL18
24 neutrophil activation GO:0042119 9.69 IL18 CCL5
25 positive regulation of osteoclast differentiation GO:0045672 9.69 TNF IL17A IFNG
26 negative regulation of amyloid-beta clearance GO:1900222 9.68 TNF IFNG
27 positive regulation of MHC class II biosynthetic process GO:0045348 9.68 IL10 IFNG
28 endothelial cell apoptotic process GO:0072577 9.67 TNF IL10
29 negative regulation of membrane protein ectodomain proteolysis GO:0051045 9.66 TIMP1 IL10
30 positive regulation of receptor binding GO:1900122 9.65 MMP9 BDNF
31 positive regulation of peptidyl-serine phosphorylation of STAT protein GO:0033141 9.65 IFNG IFNB1 IFNA1
32 type 2 immune response GO:0042092 9.64 IL18 IL10
33 negative regulation of cytokine production involved in immune response GO:0002719 9.64 TNF IL10
34 positive regulation of interleukin-23 production GO:0032747 9.63 IL17A IFNG
35 negative regulation of cytokine secretion involved in immune response GO:0002740 9.62 TNF IL10
36 positive regulation of interleukin-6 secretion GO:2000778 9.62 TNF MBP IL17A IFNG
37 positive regulation of calcidiol 1-monooxygenase activity GO:0060559 9.58 TNF IFNG
38 receptor biosynthetic process GO:0032800 9.58 TNF IL10
39 negative regulation of heterotypic cell-cell adhesion GO:0034115 9.58 MBP IL1RN IL10
40 negative regulation of viral genome replication GO:0045071 9.56 TNF MX1 IFNB1 CCL5
41 positive regulation of synoviocyte proliferation GO:1901647 9.55 TNF NEAT1
42 positive regulation of vitamin D biosynthetic process GO:0060557 9.54 TNF IFNG
43 positive regulation of interleukin-1 beta biosynthetic process GO:0050725 9.54 TNF IL17A IFNG
44 positive regulation of nitrogen compound metabolic process GO:0051173 9.52 TNF IFNG
45 response to virus GO:0009615 9.43 TNF MX1 IFNG IFNB1 FOXP3 CCL5
46 cytokine-mediated signaling pathway GO:0019221 9.36 TNF TIMP1 MMP9 IL1RN IL18 IL17A

Molecular functions related to Relapsing-Remitting Multiple Sclerosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 9.32 TNF TIMP1 IL1RN IL18 IL17A IL10

Sources for Relapsing-Remitting Multiple Sclerosis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....